Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

April 15, 2016

Primary Completion Date

April 15, 2019

Study Completion Date

December 16, 2019

Conditions
Lung Cancer
Interventions
DRUG

Vinorelbine

Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)

DRUG

Cisplatin

Cycle 1 and 2 day 1, 80 mg/m2

DRUG

Vinorelbine

Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)

DRUG

Cisplatin

Cycle 3 and 4 day 1, 80 mg/m2

RADIATION

Radiotherapy

concomitant therapy during cycles 3 and 4. Total dose: 66Gy

Trial Locations (18)

12002

Hospital Provincial de Castellón, Castellon

20014

H. de Donostia, Donostia / San Sebastian

23007

Hospital de Jaén, Jaén

27003

Hospital Universitario Lucus Augusti, Lugo

28006

H. de la Princesa, Madrid

28035

H.U. Puerta de Hierro, Madrid

28040

Hospital Fundación Jiménez Díaz, Madrid

41009

Hospital Virgen de La Macrena, Seville

46800

Hospital Lluís Alcanyís, Xàtiva

48013

Hospital de Basurto, Bilbao

50009

Hospital Clínico Lozano Blesa, Zaragoza

03203

Hospital General Universitario de Elche, Elche

08916

ICO-Badalona, Badalona

07014

H. Son Espases, Palma de Mallorca

03010

H.G.U. Alicante, Alicante

08041

Hospital de La Santa Creu I Sant Pau, Barcelona

Unknown

H. Clínico San Carlos, Madrid

07198

H. Son Llàtzer, Palma de Mallorca

All Listed Sponsors
lead

Spanish Lung Cancer Group

OTHER

NCT02709720 - Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC | Biotech Hunter | Biotech Hunter